论文部分内容阅读
目的探讨参松养心胶囊联合辛伐他汀治疗持续性房颤的临床疗效及安全性。方法将75例持续性心房颤动患者随机分为两组,对照组给予地高辛和倍他乐克治疗,治疗组给予参松养心胶囊及辛伐他汀治疗。比较治疗8周后两组主要临床症状、体征、心室率(动态心电图监测的平均心室率)、心功能改善及不良反应情况。结果两组主要临床症状、体征、心室率、心功能改善方面差异均无统计学意义(P>0.05),而不良反应的发生率,治疗组低于对照组(P<0.05)。结论参松养心胶囊联合辛伐他汀治疗持续性心房颤动有较好临床疗效,且不良反应发生率低。
Objective To investigate the clinical efficacy and safety of Shensong Yangxin Capsule combined with Simvastatin in the treatment of persistent atrial fibrillation. Methods 75 patients with persistent atrial fibrillation were randomly divided into two groups, the control group was treated with digoxin and metoprolol, the treatment group was given Shensongyangxin capsule and simvastatin treatment. The main clinical symptoms, signs, ventricular rate (mean ventricular rate of Holter monitoring), improvement of cardiac function and adverse reactions were compared between the two groups after 8 weeks of treatment. Results There was no significant difference in the main clinical symptoms, signs, ventricular rate and heart function between the two groups (P> 0.05). The incidence of adverse reactions in the treatment group was lower than that in the control group (P <0.05). Conclusion Shensongyangxin capsule combined with simvastatin has a good clinical effect in treating persistent atrial fibrillation, and the incidence of adverse reactions is low.